Labeler
Takeda Pharmaceuticals America, Inc. NDC Codes
Takeda Pharmaceuticals America, Inc. lists 151 finished drug products in the FDA NDC Directory under NDC labeler codes 0944, 42227, 47783, 54092, 59417, 63020, 64764, 68875.
Overview
Each product below links to its own NDC page with package NDCs in 10- and 11-digit form.
- Drugs
- Vyvanse, Mimrylo, Hyqvia, Rixubis, Advate, Recombinate, Iclusig, Mydayis, Alunbrig, Oseni, Intuniv, Ninlaro, Trintellix, Nesina, Gattex
- Active ingredients
- Alogliptin benzoate, Lisdexamfetamine dimesylate, Ponatinib hydrochloride, Dextroamphetamine sulfate, Dextroamphetamine saccharate, Amphetamine aspartate monohydrate, Amphetamine sulfate, Pioglitazone hydrochloride, Guanfacine hydrochloride, Vedolizumab, Brigatinib, Ixazomib citrate
- NDC labeler codes
- 0944, 42227, 47783, 54092, 59417, 63020, 64764, 68875
- Strengths (from the 100 most recently listed products)
- Alogliptin benzoate 12.5 mg/1; Alogliptin benzoate 25 mg/1; Vedolizumab 108 mg/.68mL; Lisdexamfetamine dimesylate 10 mg/1; Pioglitazone hydrochloride 30 mg/1; Human immunoglobulin g 100 mg/mL; Budesonide 2 mg/10mL; Fruquintinib 1 mg/1; Fruquintinib 5 mg/1; Lanadelumab 150 mg/mL; Lanadelumab 300 mg/2mL; Maribavir 200 mg/1; Ponatinib hydrochloride 10 mg/1; Prucalopride succinate 1 mg/1; Prucalopride succinate 2 mg/1; Mesalamine 1.2 g/1; Dextroamphetamine sulfate 3.125 mg/1; Dextroamphetamine saccharate 3.125 mg/1; Amphetamine aspartate monohydrate 3.125 mg/1; Amphetamine sulfate 3.125 mg/1
- Dosage forms
- Kit, Tablet, Film coated, Injection, Solution, Capsule, Tablet, Chewable, Capsule, Extended release, Injection, Powder, Lyophilized, For solution, Tablet, Extended release, Solution, Powder, Capsule, Delayed release, Tablet, Suspension, Tablet, Coated, Tablet, Delayed release
- Routes
- Oral, Subcutaneous, Intravenous
- Drug classes (FDA established)
- Central Nervous System Stimulant, Dipeptidyl Peptidase 4 Inhibitor, Kinase Inhibitor, Peroxisome Proliferator Receptor alpha Agonist, Peroxisome Proliferator Receptor gamma Agonist, Thiazolidinedione, Central alpha-2 Adrenergic Agonist, Integrin Receptor Antagonist, Plasma Kallikrein Inhibitor, Proteasome Inhibitor, Human Immunoglobulin G, Serotonin-4 Receptor Agonist, Phosphate Binder, Biguanide, Proton Pump Inhibitor, Xanthine Oxidase Inhibitor, Corticosteroid, Cytomegalovirus pUL97 Kinase Inhibitor, Aminosalicylate, Human Serum Albumin, GLP-2 Analog, Bradykinin B2 Receptor Antagonist, Human alpha-1 Proteinase Inhibitor, Hydrolytic Lysosomal Glucocerebroside-specific Enzyme, Human C1 Esterase Inhibitor
- HCPCS / J-code
- J3380 — Injection, vedolizumab, 1 mg
- Package NDCs
- 167 (from the 100 most recently listed products)
NDC codes
Newest listings first. Each row links to the product’s NDC page.
| Product | Strength | Form · route | Product NDC | Package NDCs (11-digit) | HCPCS |
|---|---|---|---|---|---|
| Vyvanselisdexamfetamine dimesylate | Lisdexamfetamine dimesylate 10 mg/1 | CapsuleOral | 59417-101 | 59417-0101-10 | — |
| Flexbuminalbumin human | Albumin human .05 g/mL | Injection, SolutionIntravenous | 0944-0495 | 00944-0495-05 | — |
| Entyviovedolizumab | Vedolizumab 300 mg/5mL | Injection, Powder, Lyophilized, For solutionIntravenous | 64764-300 | 64764-0300-20 | J3380 |
| Rixubiscoagulation factor ix (recombinant) | — | Kit | 0944-3026 | 00944-3026-02 | — |
| Rixubiscoagulation factor ix (recombinant) | — | Kit | 0944-3028 | 00944-3028-02 | — |
| Rixubiscoagulation factor ix (recombinant) | — | Kit | 0944-3030 | 00944-3030-02 | — |
| Rixubiscoagulation factor ix (recombinant) | — | Kit | 0944-3032 | 00944-3032-02 | — |
| Rixubiscoagulation factor ix (recombinant) | — | Kit | 0944-3034 | 00944-3034-02 | — |
| Trintellixvortioxetine | Vortioxetine hydrobromide 5 mg/1 | Tablet, Film coatedOral | 64764-720 | 64764-0720-0764764-0720-0964764-0720-30+2 more | — |
| Trintellixvortioxetine | Vortioxetine hydrobromide 10 mg/1 | Tablet, Film coatedOral | 64764-730 | 64764-0730-0764764-0730-0964764-0730-30+2 more | — |
| Trintellixvortioxetine | Vortioxetine hydrobromide 20 mg/1 | Tablet, Film coatedOral | 64764-750 | 64764-0750-0764764-0750-0964764-0750-30+2 more | — |
| Osenialogliptin and pioglitazone | Alogliptin benzoate 12.5 mg/1; Pioglitazone hydrochloride 30 mg/1 | Tablet, Film coatedOral | 64764-123 | 64764-0123-0364764-0123-0464764-0123-05 | — |
| Nesinaalogliptin | Alogliptin benzoate 12.5 mg/1 | Tablet, Film coatedOral | 64764-125 | 64764-0125-0264764-0125-3064764-0125-50+1 more | — |
| Nesinaalogliptin | Alogliptin benzoate 25 mg/1 | Tablet, Film coatedOral | 64764-250 | 64764-0250-0264764-0250-3064764-0250-50+1 more | — |
| Osenialogliptin and pioglitazone | Alogliptin benzoate 25 mg/1; Pioglitazone hydrochloride 15 mg/1 | Tablet, Film coatedOral | 64764-251 | 64764-0251-0364764-0251-0464764-0251-05 | — |
| Osenialogliptin and pioglitazone | Alogliptin benzoate 25 mg/1; Pioglitazone hydrochloride 30 mg/1 | Tablet, Film coatedOral | 64764-253 | 64764-0253-0364764-0253-0464764-0253-05 | — |
| Osenialogliptin and pioglitazone | Alogliptin benzoate 25 mg/1; Pioglitazone hydrochloride 45 mg/1 | Tablet, Film coatedOral | 64764-254 | 64764-0254-0364764-0254-0464764-0254-05 | — |
| Kazanoalogliptin and metformin hydrochloride | Alogliptin benzoate 12.5 mg/1; Metformin hydrochloride 500 mg/1 | Tablet, Film coatedOral | 64764-335 | 64764-0335-0164764-0335-6064764-0335-77+1 more | — |
| Kazanoalogliptin and metformin hydrochloride | Alogliptin benzoate 12.5 mg/1; Metformin hydrochloride 1000 mg/1 | Tablet, Film coatedOral | 64764-337 | 64764-0337-0164764-0337-6064764-0337-77+1 more | — |
| Nesinaalogliptin | Alogliptin benzoate 6.25 mg/1 | Tablet, Film coatedOral | 64764-625 | 64764-0625-3064764-0625-90 | — |
| Gattexteduglutide | Teduglutide 5 mg/.5mL | Injection, Powder, Lyophilized, For solutionSubcutaneous | 68875-0101 | 68875-0101-02 | — |
| Gattexteduglutide | — | Kit | 68875-0102 | 68875-0102-01 | — |
| Gattexteduglutide | — | Kit | 68875-0103 | 68875-0103-01 | — |
| Iclusigponatinib hydrochloride | Ponatinib hydrochloride 45 mg/1 | Tablet, Film coatedOral | 63020-534 | 63020-0534-30 | — |
| Iclusigponatinib hydrochloride | Ponatinib hydrochloride 15 mg/1 | Tablet, Film coatedOral | 63020-535 | 63020-0535-3063020-0535-60 | — |
| Advateantihemophilic factor (recombinant) | — | Kit | 0944-3047 | 00944-3047-10 | — |
| Advateantihemophilic factor (recombinant) | — | Kit | 0944-3053 | 00944-3053-02 | — |
| Advateantihemophilic factor (recombinant) | — | Kit | 0944-3051 | 00944-3051-02 | — |
| Advateantihemophilic factor (recombinant) | — | Kit | 0944-3052 | 00944-3052-02 | — |
| Advateantihemophilic factor (recombinant) | — | Kit | 0944-3054 | 00944-3054-02 | — |
| Firazyricatibant acetate | Icatibant acetate 30 mg/3mL | Injection, SolutionSubcutaneous | 54092-702 | 54092-0702-0154092-0702-0254092-0702-03 | — |
| Ceprotinprotein c concentrate human | — | Kit | 0944-4177 | 00944-4177-05 | — |
| Ceprotinprotein c concentrate human | — | Kit | 0944-4179 | 00944-4179-10 | — |
| Glassiaalpha.1-proteinase inhibitor human | .alpha.1-proteinase inhibitor human 1 g/50mL | Injection, SolutionIntravenous | 0944-2884 | 00944-2884-0100944-2884-0300944-2884-05 | — |
| Dexilantdexlansoprazole | Dexlansoprazole 30 mg/1 | Capsule, Delayed releaseOral | 64764-171 | 64764-0171-0064764-0171-0164764-0171-03+4 more | — |
| Dexilantdexlansoprazole | Dexlansoprazole 60 mg/1 | Capsule, Delayed releaseOral | 64764-175 | 64764-0175-0064764-0175-0164764-0175-02+4 more | — |
| Recombinateantihemophilic factor recombinant | — | Kit | 0944-2844 | 00944-2844-10 | — |
| Recombinateantihemophilic factor recombinant | — | Kit | 0944-2845 | 00944-2845-10 | — |
| Vprivvelaglucerase alfa | Velaglucerase alfa 2.5 mg/mL | Injection, Powder, Lyophilized, For solutionIntravenous | 54092-701 | 54092-0701-04 | — |
| Kalbitorecallantide | Ecallantide 10 mg/mL | Injection, SolutionSubcutaneous | 47783-101 | 47783-0101-01 | — |
| Intunivguanfacine | Guanfacine hydrochloride 1 mg/1 | Tablet, Extended releaseOral | 54092-513 | 54092-0513-02 | — |
| Intunivguanfacine | Guanfacine hydrochloride 2 mg/1 | Tablet, Extended releaseOral | 54092-515 | 54092-0515-02 | — |
| Intunivguanfacine | Guanfacine hydrochloride 3 mg/1 | Tablet, Extended releaseOral | 54092-517 | 54092-0517-02 | — |
| Intunivguanfacine | Guanfacine hydrochloride 4 mg/1 | Tablet, Extended releaseOral | 54092-519 | 54092-0519-02 | — |
| Recombinateantihemophilic factor recombinant | — | Kit | 0944-2841 | 00944-2841-10 | — |
| Recombinateantihemophilic factor recombinant | — | Kit | 0944-2842 | 00944-2842-10 | — |
| Recombinateantihemophilic factor recombinant | — | Kit | 0944-2843 | 00944-2843-10 | — |
| Uloricfebuxostat | Febuxostat 80 mg/1 | TabletOral | 64764-677 | 64764-0677-1164764-0677-1364764-0677-19+1 more | — |
| Uloricfebuxostat | Febuxostat 40 mg/1 | TabletOral | 64764-918 | 64764-0918-1164764-0918-1864764-0918-30+1 more | — |
| Cinryzehuman c1-esterase inhibitor | Human c1-esterase inhibitor 500 [iU]/5mL | Injection, Powder, Lyophilized, For solutionIntravenous | 42227-081 | 42227-0081-01 | — |
Takeda Pharmaceuticals America, Inc.: common questions
- What is Takeda Pharmaceuticals America, Inc.'s NDC labeler code?
- 0944, 42227, 47783, 54092, 59417, 63020, 64764, 68875. The labeler code is the first segment of each NDC. About labeler codes.
- Is there a J-code for Takeda Pharmaceuticals America, Inc.?
- Med-Code's HCPCS directory matches J3380 to these products. NDC vs J-code.
- Which NDC goes on a claim?
- The package NDC of what was given, in 11-digit form. How to convert a 10-digit NDC.